GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Deferred Policy Acquisition Costs

Emergent BioSolutions (STU:ER4) Deferred Policy Acquisition Costs


View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Emergent BioSolutions (STU:ER4) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.